Mainz Biomed NV (Mainz Biomed NV) ROCE % : -352.04% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Mainz Biomed NV ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Mainz Biomed NV's annualized ROCE % for the quarter that ended in Dec. 2023 was -352.04%.

Mainz Biomed NV ROCE % Historical Data

The historical data trend for Mainz Biomed NV's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mainz Biomed NV ROCE % Chart

Mainz Biomed NV Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-294.92

-280.18

-262.15

-211.43

-229.91

Mainz Biomed NV Quarterly Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial								-205.38	-180.00	-295.82	-296.04	-352.04

Mainz Biomed NV ROCE % Calculation

Mainz Biomed NV's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-25.486	/	( ( (20.241 - 4.243)	+	(15.409 - 9.237) )	/ 2 )
	=	-25.486	/	( (15.998	+	6.172)	/ 2 )
	=	-25.486	/	11.085
	=	-229.91 %

Mainz Biomed NV's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-22.564	/	( ( (17.907 - 11.26)	+	(15.409 - 9.237) )	/ 2 )
	=	-22.564	/	( ( 6.647	+	6.172 )	/ 2 )
	=	-22.564	/	6.4095
	=	-352.04 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Mainz Biomed NV (NAS:MYNZ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Mainz Biomed NV ROCE % Related Terms

Thank you for viewing the detailed overview of Mainz Biomed NV's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mainz Biomed NV (Mainz Biomed NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mainz Biomed NV (NAS:MYNZ) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

4TO:Germany

Address

Robert Koch Strasse 5, Sirius Gutenberg Park, Mainz, RP, DEU, 55129

Website

https://www.mainzbiomed.com

Mainz Biomed NV is engaged in developing molecular genetic diagnostic solutions for life-threatening conditions. Its main product Coloalert is a kit that includes a stool collector and shipping instructions to return the kit through regular mail to their local lab for testing and results.